Description
Vascular liver diseases are a heterogeneous group of rare disorders characterized by an impaired vascular flow in the splanchnic and/or intrahepatic vasculature. They mainly include recent portal vein thrombosis, portal cavernoma, porto-sinusoidal vascular disorder, Budd-Chiari syndrome and sinusoidal obstruction syndrome.
Vascular liver diseases commonly affect young adults, and follow a yet unpredictable course, potentially leading to severe portal hypertension and reduced survival. There is limited awareness in the medical community on vascular liver diseases, so that these diseases are currently under recognized and often misdiagnosed.
EURO-VALDI-NET aims to create a pan-European multidisciplinary co-operative network of stakeholders, bringing together scientists, clinicians, industry partners, and patients associations, to address the vascular liver diseases problems. Through the creation of shared data registries on main relevant basic and clinical aspects, conference calls, meetings, workshops, as well as training schools, this Action will coordinate efforts aiming at advancing the understanding of vascular liver diseases to translate basic
research and preclinical findings into clinical practice. For this purpose, EURO-VALDI-NET will be organized into 9 working groups:
– preclinical models
– epidemiology, extensive clinical characterization and harmonization of biosamples collection
– extensive histological characterization
– extensive radiological characterization
– development of screening tools and diagnostic biomarkers
– risk stratification and clinical trial design
– health-related quality of life and patient reported outcomes
– identification of therapeutic targets and development of new therapeutic approaches
– legal and ethics aspects
These groups will work together in order to increase knowledge on vascular liver diseases and improve recognition and management of the patients.
Action keywords
Portal vein thrombosis - Porto-sinusoidal vascular disorder - Budd-Chiari syndrome - Portal hypertension - Sinusoidal obstruction syndrome
Management Committee
Country | MC Member |
---|---|
Albania | |
Austria | |
Austria | |
Belgium | |
Bosnia and Herzegovina | |
Croatia | |
Croatia | |
Denmark | |
Denmark | |
France | |
Georgia | |
Germany | |
Germany | |
Greece | |
Greece | |
Hungary | |
Hungary | |
Israel | |
Italy | |
Latvia | |
Lithuania | |
Malta | |
Malta | |
Netherlands | |
Netherlands | |
North Macedonia | |
Norway | |
Portugal | |
Portugal | |
Romania | |
Romania | |
Serbia | |
Serbia | |
Spain | |
Spain | |
Sweden | |
Sweden | |
Switzerland | |
Switzerland | |
Türkiye | |
United Kingdom | |
United Kingdom |
Main Contacts
Action Contacts
COST Staff
Leadership
Role | Leader |
---|---|
Action Chair | |
Action Vice-Chair | |
Science Communication Coordinator | |
Grant Awarding Coordinator |
Working Groups
Number | Title | Leader |
---|---|---|
1 | Epidemiology, clinical characterization, biosamples collection and clinical trial design in VLD | TBA |
2 | Comprehensive histological characterization for PSVD | TBA |
3 | Comprehensive radiological characterization of vascular liver diseases | TBA |
4 | Development of screening tools and diagnostic biomarkers for PSVD | TBA |
5 | Health-related quality of life and patient reported outcomes in VLD | TBA |
6 | Preclinical models of VLD, therapeutic targets and new therapeutic approaches for VLD | TBA |
Express your interest to join any of the working groups by applying below.
It is required to have an e-COST profile to submit your application. If needed, create it first and then click 'Apply'.
Apply